Adenocarcinoma, Follicular - 36 Studies Found
Completed |
: Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 :
|
Active, not recruiting |
: REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas : Thyroid Neoplasms : 2006-02-03 : Drug: Lenalidomide Initial dose is 25 mg/day dose will be adjusted accordingly as needed. Dose range for |
Not yet recruiting |
: Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer Patients : Thyroid Cancer : 2016-07-27 |
Completed |
: Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy :
|
Active, not recruiting |
: Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer : Thyroid Neoplasms : 2007-09-27 :
|
Completed |
: Sutent Adjunctive Treatment of Differentiated Thyroid Cancer :
: Drug: SU011248, Sutent Sutent 37.5 mg/day will be given orally after radioactive iodine therapy. Total t |
Completed |
: Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine :
: |
Suspended |
: Pre-Operative Nodal Staging of Thyroid Cancer Using Ultra-Small Superparamagnetic Iron Oxide Magnetic Resonance Imaging (USPIO MRI): Preliminary Study :
|
Active, not recruiting |
: Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer :
: |
Completed |
: A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors :
: |